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There is currently a global epidemic of diabetes---something that was predicted decades ago by epidemiologists, who observed substantial increases in the prevalence of type 2 diabetes (T2D) among populations of indigenous people who adopted Western lifestyles \[[@CR1]--[@CR5]\]. The same trend can be seen in India: in 1990 there was only one state where noncommunicable diseases (including T2D) resulted in more deaths than communicable diseases, while in 2016 more people died of noncommunicable diseases in all 31 states, and diabetes is at the forefront of this trend \[[@CR6]\]. Lifestyle is what has driven this change, with decreases in physical activity coupled with increases in fast food consumption, portion sizes, overall calories, carbohydrate consumption, and the intake of sugar and fat, leading to marked increases in obesity and T2D \[[@CR7]--[@CR9]\].

Hotspots of diabetes in addition to India include the Middle East \[[@CR10], [@CR11]\] and China \[[@CR12], [@CR13]\]. Indeed, the large populations of India and China mean that they contribute a substantial proportion of the world's diabetes population. Epidemiological projections predict that diabetes prevalence will more than double by 2030, with the greatest increases occurring in developing countries, particularly in Asia and parts of the Middle East \[[@CR14]\]. Given that most of those with diabetes live in the developing world \[[@CR15]\], the cost of therapy is a major consideration. While advances in diabetes care are occurring at a fast pace, many of these advances are unaffordable in places like India and China, where many people live below the poverty line.

There is hence an urgent need to address the epidemic of T2D, both in developing countries and in the West. Applying the standard of care in T2D can be an important component of how we address this global challenge.
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This article does not contain any studies with human participants or animals performed by any of the authors.

Championing the Standard of Care in Clinical Practice: Interactive Case Challenge {#Sec4}
=================================================================================

Professor Mark Cooper {#Sec5}
---------------------

The details of a typical case seen in diabetes clinical practice are summarised in Table [1](#Tab1){ref-type="table"}. When this patient presents to the specialist, he is told that within 6 months of his last examination his glycosylated haemoglobin (HbA1c) has increased from 6.4% to 8.2%, meaning that he has gone from prediabetes to diabetes. He has also gained 7 lb, putting his body mass index into the obese range. The patient tells the specialist that he was recently laid off from his job, and that he hates taking pills. He wants to manage his diabetes through diet and exercise, but the specialist does not want to wait for the diet and exercise to work. The patient says that he doesn't understand why things have to change, because he feels just as well as he did 5 years ago; the specialist points out that the patient's latest tests show declining renal function, and that he needs aggressive treatment.Table 1Case presentation detailsPatient characteristics and presentation details 55-year-old male Divorced Recently lost his job Lives alone Recently diagnosed with T2D Five-year history of prediabetes, treated with diet and exercise initially, then with metformin Metformin therapy initiated approximately 2 years earlier Patient does not like taking pills; complains about having to take metformin twice daily in addition to his two once-daily antihypertensive medications Is reluctant to see a specialist

In making decisions about the most appropriate way to manage this patient, several things should be considered: adherence may be an issue for him; his renal function is reduced; he does not have any diabetes-related symptoms, but he is at risk for cardiovascular disease and diabetic kidney disease; and his diabetes is progressing, since metformin is no longer controlling his glycaemia.

The specialist decides to add a SU to the patient's regimen, starting him on gliclazide modified release (MR). This SU is a good choice for this patient because it has been shown to confer a lower risk of hypoglycaemic events compared with other SUs \[[@CR16]--[@CR20]\] for similar reductions in HbA1c \[[@CR16]\]. Gliclazide MR may be used safely in this patient with impaired renal function, \[[@CR21]\] and at risk of cardiovascular disease \[[@CR22]\]. Moreover, it's a once-daily medication, which is likely to increase adherence \[[@CR23], [@CR24]\]. Gliclazide MR has not been associated with substantial weight gain \[[@CR24], [@CR25]\], which might not be an issue for this patient, and the average HbA1c reduction with SUs is \~ 1.5% \[[@CR26]\]. The specialist explains to the patient that initially he'll be taking half a tablet per day (30 mg), and will eventually increase the dose to two 60 mg tablets per day, if needed. The patient objects to the titration, but the specialist explains why starting at a lower dose is needed to mitigate potential side effects. They discuss hypoglycaemia symptoms, and the specialist asks the patient to be adherent to the medication regimen.

At the follow-up appointment, the patient tells the specialist that he has a new job. The specialist goes through the patient's most recent tests, which show that he has responded to the SU therapy and now has HbA1c of 7.2%. His kidney function is stable. When asked about adherence, the patient admits to sometimes forgetting to take his medication in the morning, and then taking it at night; the specialists asks him not to do that, since it may increase the risk of hypoglycaemia \[[@CR27], [@CR28]\]. The specialist still has some concerns about the patient's weight, and doesn't think that diet and exercise alone will fix that, so changes in the patient's regimen may be warranted.

When considering a change in regimen, there are aspects that should be considered: since T2D is progressive, we know that metformin plus an SU will not be enough for many patients; the patient is employed now, and thus likely to be more active; he is reasonably compliant with his medication, showing a behavioural improvement, so may be open to improving his diet and exercising more; his weight is still an issue, but the fact that he still sometimes forgets his medication and then takes it when he shouldn't means that hypoglycaemia is still a concern.

In summary, a scenario like the one presented is very common in diabetes clinical practice. SUs are drugs of choice to be used with metformin due to their complementary modes of action \[[@CR29]\]. These two drugs remain the most widely prescribed anti-hyperglycaemic agents worldwide \[[@CR30]\], and have stood the test of time. Compared to other SUs, gliclazide has a lower risk of cardiovascular disease, a lower risk of hypoglycaemia and weight neutrality. In this particular case, gliclazide is a good choice as sodium glucose cotransporter 2 (SGLT2) inhibitors are generally contraindicated in patients with declining renal function, and DPP4 inhibitors are more expensive and so may not be affordable by many people in developing countries. Eventually one of the newer agents will have to be considered for a patient like this, but we at least know that agents with a long experience of use are effective in this setting.

What is the Clinical Trial Evidence for Reducing Risk? {#Sec6}
======================================================
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------------------------

The excess risks in T2D include death, myocardial infarction/angina, stroke, renal disease and end-stage renal disease (ESRD), retinopathy, neuropathy and heart failure. The mediators of these risks include non-modifiable factors such as age, sex, race and genetics, and modifiable factors such as hyperglycaemia, hypertension, hypoglycaemia, dyslipidaemia, smoking and obesity. Hyperglycaemia is a major risk factor, and there is good epidemiological data, such as National Health and Nutrition Examination Survey data, showing that the presence of hyperglycaemia decreases survival \[[@CR31]\]. Mortality data from the UK Prospective Diabetes Study (UKPDS) showed that cardiac death, sudden death and stroke were responsible for 56% of deaths; these deaths could all be considered diabetes related, and are therefore to some extent modifiable \[[@CR32]\].

Intensive Glucose Control {#Sec8}
-------------------------

In terms of modifying risk, the UKPDS has also demonstrated that tight control of blood pressure and glucose leads to the greatest reduction in risk of any diabetes-related endpoint \[[@CR33]\], including microvascular endpoints \[[@CR34]\]. Overall, the intensive glucose policy employed by the UKPDS, which maintained HbA1c at a median of 7% over a follow-up of 10 years from T2D diagnosis, decreased the risk of any diabetes-related endpoint by 12% (*p* = 0.029) \[[@CR35]\]. The risk of myocardial infarction was reduced by 16% (borderline significance *p* = 0.052), while the risk of microvascular endpoints was decreased by 25% (*p* = 0.0099) \[[@CR35]\]. Subsequent clinical trials that have employed an intensive glucose control strategy include the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) and the Action to Control CardiOvascular Risk in Diabetes (ACCORD) trials. In ADVANCE, patients were 8 years from diagnosis in both intensive treatment and control groups, with \~ 21% having a history of myocardial infarction or stroke; in this trial, target HbA1c was ≤ 6.5% \[[@CR36]\]. Over the 66-month follow-up, the differences in HbA1c between groups evolved slowly (Fig. [1](#Fig1){ref-type="fig"}), and while the difference was small, it was statistically significant. The effect of therapy on major microvascular events was significant, in favour of intensive therapy, with a relative risk reduction of 14% (*p* = 0.01); this reduction was mostly due to the effect on new or worsening nephropathy (21%; *p* = 0.006), which is a positive signal in terms of ESRD and future risk of major events \[[@CR36], [@CR37]\]. Indeed, a subsequent analysis of renal outcomes, including ESRD, demonstrated that intensive glucose control resulted in a significant reduction in the risk of ESRD compared with standard therapy \[[@CR38]\]. The ADVANCE Observational (ADVANCE-ON) study followed almost 8500 ADVANCE participants for a total follow-up time of 9.9 years, and found that reductions in the risk of ESRD persisted \[[@CR39]\].Fig. 1Effects of standard and intensive therapy on HbA1c in ADVANCE \[[@CR36]\]Figure adapted with permission from the Advance Collaborative Group, A. Patel, S. MacMahon, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560--72. \[[@CR36]\]

In the ACCORD study, the median duration of diabetes was 10 years, and one-third of patients had previous cardiovascular events while 5% had congestive heart failure \[[@CR40]\]. ACCORD had a very aggressive target HbA1c of ≤ 6.0%, and the impact of this aggressive treatment was quick but negative. ACCORD was stopped early because of a 22% relative increase in mortality in the intensive therapy group versus the standard therapy group \[[@CR40]\]. The patients in ACCORD had a high risk profile, higher than that for diabetes alone, but nevertheless the results of this trial showed that aggressive treatment of hyperglycaemia is not a safe strategy for many at-risk patient groups.

### Impact of Treatment on Diabetes Complications {#Sec9}

Trials with some of the newer glucose-lowering medications have shown positive impacts on cardiovascular events. The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients---Removing Excess Glucose (EMPA-REG OUTCOME) trial of empagliflozin and the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial of liraglutide both demonstrated significant reductions in 3-point major adverse cardiovascular events and cardiovascular death with active treatment versus placebo \[[@CR41], [@CR42]\], while the Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN 6) trial of semaglutide also demonstrated a reduction in cardiovascular events \[[@CR43]\]. Interestingly, post-trial monitoring of patients participating in the UKPDS has shown some long-term effects of glucose lowering; for example, the 25% reduction in microvascular disease seen at the end of the trial in the intensive therapy group was maintained in the 10-year follow-up, despite HbA1c having converged between the groups over time \[[@CR44]\]. All-cause mortality was not significantly different between groups at the end of the trial (hazard ratio \[HR\] 0.94; *p* = 0.44), but by 10 years post-trial, there was a significant reduction in all-cause mortality in the intensive treatment group (HR 0.87; *p* = 0.006) \[[@CR44]\]. There were no such legacy effects seen with blood pressure, with any benefits seen at the end of the trial disappearing by the 10-year follow-up. Although the mechanism of these effects is still unknown, it is clear that poor glycaemic control in the past affects outcomes over many subsequent years.

### Impacts of Other Risk Factors on Risk in T2D {#Sec10}

Glycaemic control is not the only issue to be considered when treating patients with T2D. Hypoglycaemia is now regarded as a trigger for complications and pathology. It is known that different SUs cause different amounts of hypoglycaemia \[[@CR20], [@CR45]\], and from the ACCORD study we have seen that intensive therapy leads to more hypoglycaemic episodes, which required more assistance than standard therapy \[[@CR40]\]. Hypoglycaemia is highly detrimental, and may have been a cause of the excess mortality seen in the ACCORD study \[[@CR40]\]. Certainly, the risk of hypoglycaemia should be minimised.

Dyslipidaemia should always be treated, and most patients with T2DM should be on a statin \[[@CR46]\]. A subanalysis of the '4S' study (Scandinavian Simvastatin Survival Study) showed that statin use in patients with T2D made a substantial difference in terms of decreasing cardiovascular events \[[@CR47]\], suggesting that statin therapy is something that should be considered routine in patients with T2D.

Heart failure has been increasingly recognised as a serious complication in T2D \[[@CR48]\]. Both the EMPA-REG and the Canagliflozin Cardiovascular Assessment Study (CANVAS) studies have demonstrated a positive impact of empagliflozin and canagliflozin on hospitalisation for heart failure, with empagliflozin demonstrating a 35% reduction versus placebo and canagliflozin demonstrating a 33% reduction \[[@CR41], [@CR49]\].

In summary, we have good evidence from clinical trials for the glucose-lowering efficacy of metformin, SUs and other agents. There is evidence against aggressive late glucose reduction, while the clinical trials of SGLT2 inhibitors demonstrate protection against cardiovascular events and heart failure. The GLP1 receptor agonists liraglutide and semaglutide also have good evidence supporting their role in preventing cardiovascular disease. Ultimately, prevention of complications in T2D is complex, but the evidence has given us some simple rules that can be followed.

Real-World Data in T2D: What Have We Learned About Standard-Of-Care Treatment? {#Sec11}
==============================================================================
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There is a continuum of clinical research from RCTs to real-world observational trial evidence, moving from tightly controlled, homogeneous populations to broad populations such as those seen in usual clinical practice (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR50]\]. RCTs can overcome potential issues with confounders that can be present in a broader population, while real-world studies help to answer some of the questions that RCTs may not have answered. The main differences in design between RCTs and real-world studies are summarised in Table [2](#Tab2){ref-type="table"} \[[@CR51]\].Fig. 2The continuum of clinical research \[[@CR54]\].*RCT* randomised controlled trialAdapted with permission from Saturni, S., F. Bellini, F. Braido, et al. Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther. 2014;27:129--38. \[[@CR54]\] Table 2Differences between randomised controlled trials and real-world studiesRandomised controlled trialsReal-world studiesQuantifies efficacy of drugMeasures effectiveness of therapy; includes health outcomes and resource utilizationInterventionalPrimarily observationalComparison to gold standard or placeboComparison to standard clinical practiceDouble blind/open labelOpen labelRestrictive inclusion/exclusion criteriaBroad inclusion/exclusion criteriaAdherence encouraged and monitoredSet in normal care settingFrequent study visitsNo extra visitsDrugs providedDrugs prescribed and collected in normal way

### The Gap Between RCTs and Real-World Evidence {#Sec13}

A meta-analysis that compared the effect of non-insulin antidiabetes drugs with placebo on change in HbA1c, body weight and overall hypoglycaemia from 27 RCTs found that the effect on HbA1c was similar across drug classes (reduction of 0.8--1.0%), but the effects on weight and risk of hypoglycaemia varied \[[@CR52]\]. The results from RCTs form the basis of standards of care, such as those from the American Diabetes Association \[[@CR53]\], but often there is a difference between efficacy seen in RCTs and effectiveness in the real world. Reasons for this are generally because of differences in patient populations; RCTs are typically highly selective and often exclude patients aged 65 and older, those with comorbidities, and those taking other medications \[[@CR54]\], while patients in daily practice are diverse and complex, likely to be older than 65 years, have several diseases and are likely to be taking multiple medications. Studies looking at how many real-world patients would be eligible for the landmark diabetes RCTs that have been conducted found that only 3.5--35.7% of patients in daily clinical practice would have been eligible for these studies (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR55], [@CR56]\]. This makes translating RCT evidence into clinical practice very difficult.Fig. 3Percent of real world patients eligible for Diabetes RCTsAdapted with permission from: Saunders, C., C.D. Byrne, B. Guthrie, et al. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med. 2013;30:300--8. \[[@CR56]\] and McGovern, A., M. Feher, N. Munro, and S. de Lusignan. Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use. Diabetes Ther. 2017;8:365--76. \[[@CR57]\]

Another reason why RCT results don't translate into the real world is therapeutic inertia \[[@CR57]\]. Data show that intensification of insulin therapy is delayed by a median of 6 years despite patients having HbA1c levels \> 7.5%, and the same occurs with patients receiving oral antidiabetes agents, with delays of 6.0--7.1 years occurring for patients receiving one to three oral agents \[[@CR58]\]. We have RCT evidence and guideline recommendations to support escalating therapy in a timely manner, but this is not something that happens in the real world. This inertia also occurs with patients receiving insulin therapy, with large variations between countries as to when basal insulin is initiated, and evidence that there is a failure to titrate therapy despite the fact that increasing the dose would have been appropriate \[[@CR59]--[@CR61]\]. Data show that the translation of RCT evidence is not happening in clinical practice irrespective of what medications are administered \[[@CR62]\], and observational studies show that the management of patients has not changed substantially over the last 10 years.

### Efficacy and Durability {#Sec14}

A study of 10,256 patients with T2D from the UK and Germany receiving second-line therapies showed that mean HbA1c decreased by \~  1.1% regardless of the choice of second-line agent \[[@CR63]\]. Patients who had treatment initiated within 6 months of their T2D diagnosis and patients who received second-line therapy in combination with metformin had greater reductions in HbA1c. SUs were a common choice for second-line therapy in this study \[[@CR63]\]. Another retrospective study investigating the change in HbA1c levels over 18 months following initiation of second-line treatment also found that reductions in HbA1c were similar regardless of the second-line regimen used; this study also found that the mean time between the initiation of metformin therapy and initiating second-line therapy was 2.3 years, demonstrating once more the long delays between changes in therapy \[[@CR64]\].

### Hypoglycaemia {#Sec15}

The UKPDS, ADVANCE, ACCORD, and the Veterans Affairs Diabetes Trial (VADT) studies of intensive glycaemic control all had increased rates of hypoglycaemia \[[@CR35], [@CR36], [@CR40], [@CR65]\]. In ADVANCE, the rates of severe hypoglycaemia were only slightly higher with intensive than with standard therapy (0.7 vs 0.4 events per 100 patients/year), mostly likely because of gradual and careful intensification of therapy over longer periods of time (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR36]\]. Bringing glycaemia down more quickly, such as what occurred in the ACCORD trial, was associated with an increased rate of hypoglycaemia (3.0 vs 1.0 events per 100 patients/year) \[[@CR40]\].

Real-world evidence demonstrates that rates of hypoglycaemia are higher for insulin than for non-insulin therapies (insulin: 21%; SUs and non-SU therapies: 5%) \[[@CR66]\]. Studies that have investigated rates of hypoglycaemia over the last 10 years according to age have shown that over the years there has been an increase in rates of hypoglycaemia, especially from the age of 50 years, which is surprising considering the availability of agents with a low risk of hypoglycaemia \[[@CR67]\]. This suggests that these low-risk agents are not being used appropriately.

### Cardiovascular and Mortality Outcomes with SUs {#Sec16}

A network meta-analysis of 18 studies of 14,970 patients comparing more than two SUs looked at the mortality risk associated with the different SUs, with glibenclamide as the reference, and found that some SUs were associated with a higher risk and some with a lower risk \[[@CR68]\]. A retrospective analysis of 11,141 patients with T2D did not find an increased mortality risk among the SUs, but their results did suggest that glimepiride may be better in patients with existing cardiovascular disease \[[@CR69]\]. Another meta-analysis of second- and third-generation SUs that included 47 RCTs of \> 52 weeks' duration and a total of 37,650 patients found no increase in all-cause or cardiovascular mortality with SUs as a class, with no differences identified according to follow-up time or whether the SUs were administered as monotherapy or as an add-on to metformin \[[@CR70]\].

### Practical Considerations {#Sec17}

With 80% of the people with T2D living in low- to middle-income countries, context-specific policies are required to improve access to essential medicines, including the use of generic products \[[@CR71]\]. We know that even outside developing countries, the use of SUs, metformin and insulin is still high, and cost is an important consideration globally. The Discovering Treatment Reality of Type 2 Diabetes in Real-World Settings (DISCOVER) study, which looked at diabetes-related data from 38 countries, showed that a large proportion of patients are receiving metformin, SUs, or metformin plus SUs as first-line therapy, and that many people are being given add-on SUs or metformin in the second line \[[@CR72]\]. So a large proportion of the T2D population is still using these older therapies. The PURE study investigated access to therapy in 22 countries, and found that in some countries even metformin is not available, and many pharmacies are not holding insulin \[[@CR73]\]. The World Health Organisation (WHO) recommends SU as an add-on therapy to metformin or SU alone in patients intolerant to metformin \[[@CR74]\], which is a cost-effective option for second-line therapy \[[@CR75], [@CR76]\].

In conclusion, well-designed real-world studies complement RCTs. We have extensive experience in using SUs over more than 60 years, and the risks and benefits of these agents are well understood. They have good efficacy and durability and a favourable cost/efficacy/safety ratio. Overall, therapies for T2D are initiated far too late, and we need to invest in holistic therapy for patients in a climate of limited resources.

Concluding Remarks {#Sec18}
==================

Dr Viswanathan Mohan {#Sec19}
--------------------

In clinical practice there are patients with T2D who have survived even for 50--60 years after their T2D diagnosis; for those patients, the only agents available to them when they were diagnosed were metformin and SUs \[[@CR77]\]. Some of those patients are still taking this regimen, demonstrating the long-term efficacy of those older drugs. The WHO recommendations are very appropriate. It is too early to consider not using SUs and metformin because they still do have a place in therapy. Moreover, these drugs are perhaps the only ones affordable by the majority of patients in developing countries like India, where over 70% of patients pay 'out of pocket' for medicines \[[@CR78]\]. The newer drugs are useful, particularly for specific indications or needs, such as a patient with cardiovascular risk, or a need for weight loss. So having more options for therapy is a positive thing.

This symposium took place on the 3rd of October 2018 as part of the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany.
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